. 2022 May;72(5):505-510.
–
–
[Article in
French]
Affiliations
Expand
Affiliations
- 1 Department of Infectious and Tropical Diseases, Hospices Civils de Lyon, France.
- 2 Department of Infectious and Tropical Diseases, Hospices Civils de Lyon, France – International Center for Infectious Disease Research (CIRI), Inserm 1111, Claude-Bernard Lyon-1 University, National Center for Scientific Research, Joint Research Unit 5308, École Normale Supérieure of Lyon, University of Lyon, France.
–
–
–
Item in Clipboard
–
[Article in
French]
Clement Javaux et al.
Rev. Prat.
2022 May.
Display options
Format
Abstract
PubMed
PMID
–
–
–
–
. 2022 May;72(5):505-510.
–
–
Affiliations
- 1 Department of Infectious and Tropical Diseases, Hospices Civils de Lyon, France.
- 2 Department of Infectious and Tropical Diseases, Hospices Civils de Lyon, France – International Center for Infectious Disease Research (CIRI), Inserm 1111, Claude-Bernard Lyon-1 University, National Center for Scientific Research, Joint Research Unit 5308, École Normale Supérieure of Lyon, University of Lyon, France.
–
–
Item in Clipboard
–
–
Display options
Format
AbstractPubMedPMID
—–
MEDICAL MANAGEMENT OF COVID-19, EXCLUDING INTENSIVE CARE Management of Covid-19 is primarily guided by the severity of the respiratory involvement. Covid-19 is mostly asymptomatic or pauci-symptomatic allowing the ambulatory setting associated with isolation measures going from 5 to 10 days depending on the circumstances. Nirmatrelvir/ritonavir (Paxlovid) is currently the oral treatment for Covid-19 in adult patients not requiring oxygen therapy and at risk of severe disease in the absence of contraindications. For hospitalized patients requiring oxygen support, corticosteroid therapy and anticoagulation are the main supportive treatments in association with measures preventing secondary cases. The antiviral approach is limited in this context, consisting in passive immunotherapy (mostly neutralizing monoclonal antibodies) or direct-acting antivirals active on the dominant variant and that have demonstrated clinical efficacy.
–
MEDICAL MANAGEMENT OF COVID-19, EXCLUDING RESUSCITATION The medical management of SARS-CoV-2 infection is mainly guided by the severity of the respiratory impairment. In the general population, the infection is most often asymptomatic or paucisymptomatic, authorizing outpatient management, subject to isolation measures of five to ten days depending on the circumstances. Pre-exposure prevention by monoclonal antibodies should be offered whenever possible in immunocompromised patients. In the absence of contraindications, the nirmatrelvir-ritonavir (Paxlovid) combination is currently the outpatient oral curative treatment for adult patients not requiring oxygen therapy and at risk of a severe form. For oxygen-requiring hospitalized patients, corticosteroid therapy and anticoagulation are the main complementary treatments, in combination with preventive measures for the eviction of secondary cases. The antiviral approach is limited in this context, relying on passive immunotherapy (essentially neutralizing monoclonal antibodies) or active antivirals on the dominant variant and having demonstrated clinical efficacy.
–
Keywords:
Antibodies, Monoclonal; Antiviral Agents; Covid-19.
–
Conflict of interest statement
The authors declare that they have no conflict of interest.
–
–
–
